---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-025295"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2025-07-09T23:59:59+00:00"
generated_at: "2026-05-18T08:50:51.018401+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics secures $10M line of credit from Chairman Uihlein; extends existing debt to Sept 2026

## Summary
- Richard E. Uihlein provides up to $10M unsecured line of credit; draws through April 2026, principal & interest due Sept 30, 2026.
- Interest at Applicable Federal Rate (currently 4.05%) plus 2%; conversion price floor $3.00 per share.
- Up to 200,000 warrants issued ratably; exercise price 150% of closing price, capped at $10, floor $3.
- Company extends existing $81M in convertible notes & lines of credit to September 30, 2026.
- Board approves $100K retention bonuses for CMO Dr. Khurram Jamil & CFO Jack Callicutt; partnership bonus if belapectin deal by Dec 2025.

## SEC filing metadata
- accession: 0001140361-25-025295
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2025-07-09T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036125025295/0001140361-25-025295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036125025295/ef20051584_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-025295
- JSON: https://secwatch.observer/filing/0001140361-25-025295.json
- Plain text: https://secwatch.observer/filing/0001140361-25-025295.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.